During the past decade, Pro Scientia med conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Pro Scientia med" are "Diabetes Mellitus, Type 2" (1 trials), "Impaired Glucose Tolerance" (1 trials) and "Type 2 Diabetes Mellitus" (1 trials). Many other conditions were trialed in "Pro Scientia med" in a lesser frequency.

Most popular intervention types in "Pro Scientia med" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Canakinumab 150 mg" (1 trials), "Metformin" (1 trials), "Placebo" (1 trials), "Placebo to Canakinumab" (1 trials) and "Sitagliptin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pro Scientia med" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Pro Scientia med". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Pro Scientia med, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pro Scientia med, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".